| Literature DB >> 28349255 |
B C T van Bussel1,2,3, R M A Henry1,3,4, C G Schalkwijk1,3,4, J M Dekker5,6, G Nijpels6,7, E J M Feskens3,8, C D A Stehouwer9,10,11,12,13.
Abstract
PURPOSE: Endothelial dysfunction and low-grade inflammation are key phenomena in the pathobiology of cardiovascular disease (CVD). Their dietary modification might explain the observed reduction in CVD that has been associated with a healthy diet rich in fruit, vegetables and fish, low in dairy products and with moderate alcohol and red wine consumption. We investigated the associations between the above food groups and endothelial dysfunction and low-grade inflammation in a population-based cohort of Dutch elderly individuals.Entities:
Keywords: Diet; Elderly; Endothelial dysfunction; Inflammation; Red wine
Mesh:
Substances:
Year: 2017 PMID: 28349255 PMCID: PMC5959974 DOI: 10.1007/s00394-017-1420-4
Source DB: PubMed Journal: Eur J Nutr ISSN: 1436-6207 Impact factor: 5.614
Population characteristics, diet, endothelial dysfunction and low-grade inflammation according to categories of alcohol consumption
| Categories of alcohol consumption | P-trend | |||
|---|---|---|---|---|
| None | Moderate | High | ||
| Population characteristics | ||||
| Age, year | 70.7 ± 7.1 | 68.8 ± 7.2 | 66.8 ± 6.9 | <0.001 |
| Sex, Men/Women | 34/105 | 237/177 | 131/117 | <0.001 |
| Glucose metabolism status* | ||||
| Normal glucose metabolism, % | 23.9 | 40.4 | 36.9 | |
| Impaired glucose metabolism, % | 18.1 | 23.8 | 24.1 | |
| Diabetes mellitus type 2, % | 58.0 | 35.8 | 39.0 | 0.006 |
| Body mass index, kg/m2 | 28.1 ± 5.0 | 27.5 ± 4.1 | 27.8 ± 3.8 | 0.591 |
| Current smoking, % | 12.9 | 13.3 | 19.4 | 0.048 |
| Prior cardiovascular disease, % | 62.8 | 52.2 | 52.7 | 0.105 |
| Low-educational level, % | 41.3 | 26.5 | 19.8 | <0.001 |
| Physical activity, METs hour/week | 49 [21–99] | 81 [47–129] | 85 [51–132] | <0.001 |
| Systolic blood pressure, mmHg | 142 ± 22 | 142 ± 20 | 142 ± 20 | 0.651 |
| Diastolic blood pressure, mmHg | 83 ± 11 | 83 ± 11 | 84 ± 11 | 0.378 |
| Anti-hypertensive medication, % | 51.8 | 37.0 | 35.9 | 0.006 |
| Total cholesterol, mmol/L | 5.7 ± 1.1 | 5.6 ± 1.1 | 5.9 ± 0.9 | 0.051 |
| HDL cholesterol, mmol/L | 1.3 ± 0.4 | 1.3 ± 0.4 | 1.5 ± 0.4 | <0.001 |
| LDL cholesterol, mmol/L | 3.6 ± 1.0 | 3.6 ± 0.9 | 3.6 ± 0.8 | 0.585 |
| Triglycerides, mmol/L | 1.5 [1.1–2.2] | 1.3 [1.0–1.8] | 1.3 [1.0–2.0] | 0.838 |
| Lipid-lowering medication, % | 18.0 | 15.9 | 17.7 | 0.931 |
| Albuminuria [albumin/creatinine ratio > 2 (mg/mmol)], % | 15.1 | 16.3 | 13.8 | 0.624 |
| Serum creatinine, µmol/L | 91.6 ± 17.1 | 96.4 ± 17.7 | 95.6 ± 16.1 | 0.083 |
| eGFR, mL/min/1.73 m2 | 60.9 ± 12.4 | 63.5 ± 11.2 | 64.2 ± 11.1 | 0.014 |
| Diet | ||||
| Energy intake, kJ/d | 7063 ± 2323 | 8032 ± 2065 | 9070 ± 3709 | <0.001 |
| Ethanol, g/d | 0.0 [0.0–0.0] | 3.5 [1.0-8.1] | 28.7 [20.1–40.0] | By definition |
| Red wine, dL/d | 0.0 [0.0–0.0] | 0.0 [0.0–14.3] | 12.1 [0.0–85.7] | <0.001 |
| Vegetables, g/d | 121 ± 50 | 125 ± 49 | 136 ± 61 | 0.005 |
| Fruit, g/d | 302 ± 177 | 288 ± 168 | 271 ± 164 | 0.068 |
| Fish, g/d | 4.4 [0.0-14.9] | 8.8 [2.8–16.8] | 13.2 [4.3–18.0] | <0.001 |
| Dairy products, g/d | 450 ± 311 | 470 ± 270 | 413 ± 210 | 0.072 |
| Endothelial dysfunction | ||||
| Endothelial dysfunction score, SD | 0.15 ± 0.66 | 0.002 ± 0.66 | −0.08 ± 0.59 | 0.002 |
| von Willebrand factor, % | 167 ± 53 | 155 ± 60 | 148 ± 46 | 0.002 |
| Soluble endothelial selectin, µg/L | 20 ± 9 | 19 ± 8 | 20 ± 8 | 0.426 |
| Soluble thrombomodulin, µg/L | 3.6 ± 1.0 | 3.6 ± 0.9 | 3.4 ± 0.9 | 0.012 |
| Soluble vascular cell adhesion molecule 1, µg/L | 437 ± 102 | 417 ± 103 | 398 ± 87 | <0.001 |
| Soluble intercellular adhesion molecule 1, µg/L | 275 ± 68 | 261 ± 64 | 261 ± 62 | 0.115 |
| Flow-mediated vasodilation | ||||
| Baseline diameter, mm | 4.46 ± 0.75 | 4.71 ± 0.73 | 4.72 ± 0.76 | 0.014 |
| Peak diameter after cuff release, mm | 4.60 ± 0.75 | 4.87 ± 0.71 | 4.92 ± .0.75 | 0.001 |
| Peak diameter change after cuff release, mm | 0.14 ± 0.11 | 0.16 ± 0.17 | 0.20 ± 0.18 | 0.001 |
| Low-grade inflammation | ||||
| Low-grade inflammation score, SD | 0.13 ± 0.61 | -0.02 ± 0.61 | −0.03 ± 0.65 | 0.051 |
| C-reactive protein, mg/L | 3.1 [1.5–5.9] | 2.3 [1.2–4.9] | 2.4 [1.1–4.3] | 0.040 |
| Serum amyloid A, mg/L | 2.6 [1.3–3.5] | 1.7 [1.0–3.2] | 1.7 [1.0–3.2] | 0.027 |
| Interleukin-6, ng/L | 1.7 [1.1–2.5] | 1.5 [1.1–2.2] | 1.4 [1.0–2.4] | 0.597 |
| Interleukin-8, ng/L | 15.5 [11.8–20.4] | 11.0 [14.0–18.1] | 13.9 [10.9–19.3] | 0.953 |
| Tumour necrosis factor α, ng/L | 9.2 ± 2.5 | 8.8 ± 3.0 | 8.8 ± 3.1 | 0.361 |
| Soluble intercellular adhesion molecule 1, µg/L | 275 ± 68 | 261 ± 64 | 261 ± 62 | 0.115 |
Data are means ± SD, median [interquartile range] or percentages, as appropriate, according to the following categories of alcohol consumption: nonconsumers (n = 139); moderate consumers (men: ethanol intake 0–20 g/d; women: ethanol intake 0–10 g/d; n = 414); and high consumers (men: ethanol intake > 20 g/d; women: ethanol intake > 10 g/d; n = 248); P-trend by linear regression analysis for continuous variables and by Chi-square test for proportions
METs metabolic equivalents; HDL high-density lipoprotein; LDL low-density lipoprotein; eGFR estimated glomerular filtration rate according to Levey’s [Chronic Kidney Disease Epidemiology Collaboration (CKD-epi)] formula for the following four strata (only Caucasians present in the Hoorn study population); (1) women, serum creatinine ≤ 62 µmol/L: eGFR = 144 × (serum creatinine/0.7)−0.329 × (0.993)Age ; (2) women, serum creatinine > 62 µmol/L: eGFR = 144 × (serum creatinine/0.7)−1.209 × (0.993)Age ; (3) men, serum creatinine ≤ 80 µmol/L: eGFR = 141 × (serum creatinine/0.9)−0.411 × (0.993)Age ; (4) men, serum creatinine > 80 µmol/L: eGFR = 141 × (serum creatinine/0.9)−1.209 × (0.993)Age [25]
*Normal glucose metabolism: fasting plasma glucose <6.1 mmol/L and 2-h post-load plasma glucose <7.8 mmol/L; impaired glucose metabolism: impaired fasting plasma glucose between 6.1 and 7.0 mmol/L and impaired glucose tolerance defined as a 2-h post-load plasma glucose between 7.8 and 11.1 mmol/L; diabetes mellitus type 2: fasting plasma glucose >7.0 mmol/L and/or 2-h post-load plasma glucose ≥11.1 mmol/L
Associations between categories of alcohol and red wine consumption and endothelial dysfunction and low-grade inflammation
| Model | Endothelial dysfunction | Low-grade inflammation | ||||
|---|---|---|---|---|---|---|
| Biomarker score | Flow-mediated vasodilation | Biomarker score | ||||
| β (95% CI) |
| β (95% CI) |
| β (95% CI) |
| |
| Alcohol | ||||||
| 1 | ||||||
| None | – | – | – | |||
| Moderate | −0.16 (−0.37; 0.04) 0.116 | 0.01 (−0.21; 0.23) 0.952 | −0.12 (−0.32; 0.09) 0.275 | |||
| High | 0.23 (−0.45;-0.01) 0.040 | 0.051 | 0.16 (−0.08; 0.39) 0.200 | 0.114 | −0.07 (−0.30; 0.16) 0.539 | 0.717 |
| 2 | ||||||
| None | – | – | – | |||
| Moderate | −0.13 (−0.33; 0.07) 0.204 | −0.02 (−0.24; 0.20) 0.843 | −0.08 (−0.28; 0.13) 0.455 | |||
| High | −0.23 (−0.45; −0.01) 0.040 | 0.038 | 0.17 (−0.06; 0.41) 0.150 | 0.061 | −0.07 (−0.30; 0.15) 0.515 | 0.594 |
| 3 | ||||||
| None | – | – | – | |||
| Moderate | −0.13 (−0.33; 0.07) 0.212 | −0.03 (−0.25; 0.19) 0.796 | −0.08 (−0.28; 0.13) 0.455 | |||
| High | −0.22 (−0.45; −0.003) 0.047 | 0.047 | 0.17 (−0.07; 0.41) 0.163 | 0.073 | −0.06 (−0.29; 0.16) 0.574 | 0.663 |
| 4a | ||||||
| None | – | |||||
| Moderate | −0.12 (−0.33; 0.08) 0.226 | |||||
| High | −0.18 (−0.41; 0.05) 0.122 | 0.137 | ||||
| Red wine | ||||||
| 1 | ||||||
| Nonconsumers | – | – | – | |||
| Consumers | −0.21 (−0.35; −0.07) 0.004 | 0.08 (−0.07; 0.23) 0.291 | −0.23 (−0.37; −0.09) 0.002 | |||
| 2 | ||||||
| Nonconsumers | – | – | – | |||
| Consumers | −0.16 (−0.31; −0.02) 0.028 | 0.07 (−0.08; 0.23) 0.361 | −0.19 (−0.34; −0.04) 0.013 | |||
| 3 | ||||||
| Nonconsumers | – | – | – | |||
| Consumers | −0.16 (−0.30; −0.01) 0.034 | 0.07 (−0.09; 0.22) 0.414 | −0.18 (−0.33; −0.04) 0.016 | |||
| 4b | ||||||
| Nonconsumers | – | – | ||||
| Consumers | −0.15 (−0.30; −0.003) 0.045 | −0.19 (−0.34; −0.04) 0.012 | ||||
Data are standardized regression coefficients, with their 95% confidence intervals, indicating the difference in the endothelial dysfunction biomarker score, flow-mediated vasodilation (FMD) and the low-grade inflammation biomarker score (all in SD) between categories of alcohol consumption, with moderate (men: ethanol intake 0–20 g/d; women: ethanol intake 0–10 g/d) and high consumers (men: ethanol intake >20 g/d; women: ethanol intake >10 g/d) compared to nonconsumers (-, reference group); and between red wine consumers [median (IQR) 28.6 (5.5–71.4) dL/d] and nonconsumers (-, reference group), with P-values and P-trend by linear regression analyses
Analyses on biomarker scores include 738 participants and higher values indicate worse function
Analyses on FMD include 643 participants and lower values indicate worse function; to calculate peak diameter change in millimetres multiply by 0.167 (SD)
Model 1: adjusted for sex, age, glucose metabolism status, energy intake and for FMD additionally for baseline diameter and flow increase
Model 2: model 1 additionally adjusted for body mass index, current smoking, prior cardiovascular disease, educational level and physical activity
Model 3: model 2 additionally adjusted for vegetable, fruit, fish and dairy product consumption
Model 4a: model 2 additionally adjusted for red wine (dL/d)
Model 4b: model 2 additionally adjusted for alcohol (g/d)
Fig. 1Endothelial dysfunction biomarkers (a) and low-grade inflammation biomarkers (b) for red wine consumers, compared to nonconsumers. Dots show scores and individual biomarker associations adjusted conform models 2, with whiskers indicating their 95% confidence intervals. Higher biomarkers indicate worse function and more inflammation. ED endothelial dysfunction biomarker score; vWf von Willebrand factor; sICAM-1 soluble intercellular adhesion molecule 1; sVCAM-1 soluble vascular cell adhesion molecule 1; sTM soluble thrombomodulin; sE-selectin soluble endothelial selection; LGI low-grade inflammation biomarker score; TNF-a tumour necrosis factor alpha; ln natural log normalized; CRP C-reactive protein; IL-6 interleukin-6; SAA serum amyloid A; IL-8 interleukin 8